Document:

Restricted Stock Grant Agreement with Patrick J. Sullivan

 Exhibit 10.13 
 Hologic, Inc. Amended and Restated 1999 Equity Incentive Plan 
 Restricted Stock Unit Award 

 Patrick J. Sullivan was awarded $1.5 million value in Restricted Stock Units (“RSUs”) 
  

			
	 Grant Date: October 22, 2007
	 	Restriction Lapse Date: October 22, 2010

 Restricted Stock Unit Grant (the “Grant”) – additional terms 
 1. Grant. The Compensation Committee (“Committee”) of the Board of Directors of Hologic, Inc. (“Company”) has granted [# of shares based
on closing price of Hologic common stock on October 22, 2007] Restricted Stock Units (“RSUs”) to Patrick J. Sullivan (the “Grantee”). Each RSU entitles the Grantee to receive from the Company (i) one share of Hologic, Inc.
common stock, par value $0.01 per share, and (ii) the right to receive notional dividend equivalents, each in accordance with the terms of (a) this Grant, (b) the Hologic, Inc. Amended and Restated 1999 Equity Incentive Plan (the
“Plan”), (c) any rules and procedures adopted by the Committee, and (d) that certain Amended and Restated Retention and Severance Agreement dated August 17, 2007, between the Company and the Grantee (the “Retention
Agreement”). 
 2. Restricted Stock Units. The Company will deliver to the Grantee, as of the Restriction Lapse Date, one share of Company
common stock, par value $0.01, for each RSU of the Grant which become vested on the Restriction Lapse Date as set forth in paragraph 4 (the “Issue Date”). 
 3. Dividend Equivalents. Until the Issue Date, whenever dividends are paid or distributed with respect to the Company’s common stock, the Grantee shall be entitled to receive notional dividend
equivalents in an amount equal in value to the amount of the dividend or property distributed on a single share of common stock. multiplied by the number of RSUs credited to the Grantee’s account as of the record date for such dividend or
distribution. Payment of the notional dividend equivalents paid on RSUs will be withheld by the Company and shall be delivered to the Grantee as of the Issue Date, if and only to the extent that the RSUs have vested as of said date, as set forth in
paragraph 4.
 4. Vesting. All of the RSUs granted hereby will vest on the Restriction Lapse Date only if the Grantee remains employed by the
Company as set forth in the Retention Agreement at all times prior to the Restriction Lapse Date. If such employment of Grantee with the Company is terminated prior to the Restriction Lapse Date for other than Cause or Good Reason (as such terms are
defined in Sections 1.2 and 1.5, respectively, of the Retention Agreement), then the RSUs shall not vest, this Agreement shall terminate and Grantee shall have no further rights hereunder, including without limitation any rights to receive any
Dividend Equivalents as set forth in paragraph 3. In the event that the Grantee’s employment with the Company is terminated by the Company for other than Cause or the Grantee terminates such employment for Good Reason, then the RSUs shall be
immediately and fully vested on the date of such termination. Reference is made to that certain Amended and Restated Change of Control Agreement dated October 30, 2006, between the Company and the Grantee (the “Change of Control
Agreement”). Notwithstanding anything to the contrary in the Change of Control Agreement, the vesting of the RSUs shall not be accelerated by a Change of Control (as such term is defined in the Change of Control Agreement). 
 5. Voting and other Rights. The Grantee shall have no rights of ownership in the RSUs or the underlying shares of Company common stock, and shall have no
right to vote the RSUs or the underlying sharers of Company common stock until the date on which the RSUs vest.  
 6. Incorporation of Plan and
Retention Agreement. Except as otherwise expressly provided herein, all terms used in this Grant have the same meaning as given such terms in the Plan. This Grant incorporates and is subject to the provisions of the Plan and the Retention
Agreement, and such Plan and Retention Agreement shall be deemed a part of the Grant for all purposes. A copy of the Plan will be furnished upon request. 
 7. 409A Compliance. The Company may, in its sole and absolute discretion, delay payments hereunder or make such other modifications with respect to the issuance of stock hereunder as it reasonably deems necessary to comply
with Section 409A of the Code and interpretative guidance thereunder. 

 8. Entire Agreement. This Grant, the Plan, and the Retention Agreement, contain all of the provisions
applicable to the RSUs and no other statements, documents or practices may modify, waive or alter such provisions unless expressly set forth in writing, signed by an authorized officer of the Company and delivered to the Grantee. 
  

							
	 Patrick J. Sullivan
	 		 	Hologic, Inc.
				
	  
	 		 	By:	 	 /S/    GLENN P. MUIRSeparation and Release Agreement with Daniel J. Levangie

 Exhibit 10.14 
 Separation and Release Agreement 
 SEPARATION AND RELEASE AGREEMENT entered into as of this 22nd day of October, 2007 (the “Agreement”) by and among Hologic, Inc., a
Delaware corporation with its principal place of business at 35 Crosby Drive, Bedford, Massachusetts 01730 (“Hologic”), Cytyc Corporation, a Delaware corporation with its principal place of business at 250 Campus Drive, Marlborough,
Massachusetts 01752 (“Cytyc”), and Daniel J. Levangie, an individual having his principal residence at 120 Commonwealth Avenue, Apt. 4, Boston, Massachusetts 02116 (the “Executive”). 
 RECITAL 
 WHEREAS, in
connection with the execution and delivery of that certain Agreement and Plan of Merger by and among Hologic, Nor’easter Corp., a Delaware corporation (“Nor’easter”) and Cytyc Corporation, dated as of May 20, 2007 (the
“Merger Agreement”), pursuant to which Cytyc, subject to satisfaction or waiver of the conditions set forth therein, has agreed to merge with and into Nor’easter (the “Merger”); 
 WHEREAS, Executive and Cytyc entered into that certain Change of Control Agreement, as amended, dated July 23, 2003 (the “Cytyc Change
of Control Agreement”); 
 WHEREAS, Executive and Hologic have entered into that certain Amended and Restated Retention and
Separation Agreement dated August 17, 2007 (the “Retention Agreement”), subject to and effective upon the consummation of the Merger; 
 WHEREAS, Executive and Hologic entered into that certain Intellectual Property Rights and Noncompetition Agreement, dated August 17, 2007 (the “Noncompetition Agreement”); 
 WHEREAS, Executive and Hologic entered into a certain Amended and Restated Change of Control Agreement, dated August 17, 2007 (the
“Hologic Change of Control Agreement”); and 
 WHEREAS, Executive and Cytyc desire to reach a mutual understanding and
acceptance of the terms and conditions related to Executive’s resignation from employment with Cytyc, effective as of the closing of the Merger. 
 AGREEMENT 
 NOW, THEREFORE, in consideration of the mutual promises and covenants
herein contained it is hereby agreed as follows: 
 1. Separation Date. Executive shall cease to be an employee of Cytyc immediately
prior to the Effective Time (as such term is defined in the Merger Agreement) of the Merger (the “Separation Date) and shall not become an employee of Hologic; provided that this Release Agreement is not revoked in accordance with
Section 8 herein. The Executive shall execute and deliver a letter of resignation to Cytyc in substantially the form attached as Exhibit A hereto and dated as of the Separation Date. 
  

 -1- 

 2. Severance. In consideration of Executive’s accepting and not revoking this Release
Agreement: 
 (a) In addition to all other amounts payable to Executive by law (including, without limitation, final wages and accrued but
unused vacation), Cytyc shall pay Executive a lump sum payment equal to $3,840,644.00 upon expiration of the revocation period described in Section 8. The payments indicated in this Section 2 hereof shall be net of all other withholdings
required by law, including, without limitation, applicable federal and state taxes and shall be in lieu of, and full satisfaction thereof and any and all payments due pursuant to Section 6.1 of the Retention Agreement and Section 2 of the
Cytyc Change of Control Agreement. The Executive agrees and acknowledges that in no event is he entitled to payment of a Retention Bonus or issuance of Restricted Stock Units under Sections 3 and 3.1, respectively, of the Retention Agreement. The
Company and Executive agree that the payment due the Executive under Section 2(a)(i)(B) of the Cytyc Change of Control Agreement is included in the amount set forth in this Section 2(a) and the Company has no further obligation thereto.

 (b) Cytyc shall continue to pay the employer and employee portion of premiums for COBRA continuation coverage for eighteen
(18) months following the Separation Date. 
 (c) This Agreement shall be subject to and conditioned upon the consummation of the Merger
and shall not become effective until the Effective Date (as defined in Section 8 below). In the event that the Merger Agreement is terminated prior to the Effective Time (as defined in the Merger Agreement), then this Agreement shall become
null and void ab initio and be of no further force and effect. 
 3. Release. 
 (a) In consideration for, among other things, the payments to be made pursuant to Sections 2(a) and 2(b) above, Executive, for himself, his agents, legal
representatives, assigns, heirs, distributes, devisees, legatees, administrators, personal representatives and executors (collectively, the “Releasing Parties”), hereby releases and discharges, to the extent permitted by law, Cytyc and its
present and past subsidiaries and affiliates, its and their respective successors and assigns, and the present and past shareholders, officers, directors, employees, agents and representatives of each of the foregoing (collectively, the
“Releasees”), from any and all claims, demands, actions, liabilities and other claims for relief and remuneration whatsoever, whether known or unknown, from the beginning of the world to the date Executive signs this Release Agreement, but
otherwise including, without limitation, any claims arising out of or relating to Executive’s employment with and termination of employment from Cytyc Corporation, for wrongful discharge, for breach of contract, for discrimination or
retaliation under any federal, state or local fair employment practices laws, including, Title VII of the Civil Rights Act of 1964 (as amended by the Civil Rights Act of 1991), the Family and Medical Leave Act, the Americans with Disabilities Act,
the Age Discrimination in Employment Act, for defamation or other torts, for wages, bonuses, incentive compensation, stock, stock options, vacation pay or any other compensation or benefit and any claims under any tort or contract (express or
implied) theory, and any of the claims, matters and issues which could have been asserted by the Releasing Parties against the Released Parties in any legal, administrative or other proceeding in any jurisdiction. Notwithstanding the above, nothing
in this release is intended to release or waive 

  

 -2- 

 
your right to COBRA, unemployment insurance benefits, any accrued pension rights or any other vested retirement benefits, the right to seek enforcement of
this Agreement or any rights referenced in Section 4 below. 
 (b) In consideration of the Release provided by the Executive in
Section 3(a) above, Cytyc hereby releases and discharges, to the extent permitted by law, the Executive from any and all claims, demands, actions and liabilities and other claims for relief or remuneration whatsoever, whether known or unknown,
from the beginning of the world to the date Executive signs this Release Agreement; provided, however, nothing herein shall eliminate or limit Executive’s personal liability for any acts or omissions that were not in good faith or which
involved intentional misconduct or knowing violation of the law. 
 4. Service as Director. Notwithstanding anything herein to the
contrary, the Executive and Hologic acknowledge and agree that the Executive shall continue as a director of Hologic as provided for in the Merger Agreement. The Executive and Hologic agree and acknowledge that the rights and obligations of either
party with respect to the Executive’s status as a director of Hologic including, without limitation, his entitlement to compensation as a non-employee Director thereof pursuant to Hologic’s Board of Directors’ Compensation Plan shall
not be released or waived. 
 5. Survival. It is understood and agreed that, with the exception of (i) obligations of Executive
under the Noncompetition Agreement, (ii) Section 3 of the Cytyc Change of Control Agreement, (iii) Section 8 of the Retention Agreement, and (iv) any of the Executive’s rights to indemnification as provided in
Cytyc’s certificate of incorporation, bylaws or any indemnification agreement between Cytyc and the Executive (it being acknowledged and agreed by the Executive that, as of the date of this Agreement, there are no amounts owing to the Executive
pursuant to any such indemnification rights), all which shall remain fully binding and in full effect subsequent to the execution of this Release Agreement, the Release set forth in the preceding Section 3(a) is intended and shall be deemed to
be a full and complete release of any and all claims that Executive or Releasing Parties may or might have against Releasees out of any occurrence arising on or before the Execution Date and said Release Agreement is intended to cover and does cover
any and all future damages not now known to Executive or which may later develop or be discovered, including all causes of action therefore and arising out of or in connection with any occurrence arising on or before the Execution Date. 

6. Exceptions. This Release Agreement does not (i) prohibit or restrict the Executive from communicating, providing relevant information
to or otherwise cooperating with the EEOC or any other governmental authority with responsibility for the administration of fair employment practices laws regarding a possible violation of such laws or responding to any inquiry from such authority,
including an inquiry about the existence of this Release Agreement or its underlying facts, or (ii) preclude Executive from benefiting from classwide injunctive relief awarded in any fair employment practices case brought by any governmental
agency, provided such relief does not result in Executive’s receipt of any monetary benefit or substantial equivalent thereof. 
  

 -3- 

 7. ADEA Release. By signing and returning this Release Agreement, Executive acknowledges that
Executive: 
 (a) has carefully read and fully understands the terms of this Release Agreement; 
 (b) is entering into this Release Agreement voluntarily and knowing that Executive is releasing claims that Executive has or believes Executive may have
against the Releasees; and 
 (c) has obtained advice of counsel with respect to the negotiation and execution of this Release Agreement.

 8. ADEA Revocation. Executive acknowledges that he has been given the opportunity to consider this Release Agreement for forty-five
days before signing it. For a period of seven (7) days from the date Executive signs this Release Agreement, Executive has the right to revoke this Release Agreement by written notice to the undersigned. This Release Agreement shall not become
effective or enforceable until the expiration of the revocation period. This Release Agreement shall become effective on the first business day following the expiration of the revocation period (the “Effective Date”). 
 9. Public Statement. Executive hereby agrees that he will refrain from making any derogatory or false statements with respect to Cytyc or Hologic
or any of their officers, directors, Executives, advisors, customers, shareholders or other related or affiliated parties or any other Releasees. Cytyc or Hologic hereby agree that their officers, directors, shareholders or other related or
affiliated parties shall refrain from making any derogatory or false statements with respect to Executive. Cytyc or Hologic will also direct their employees and advisors to refrain from making derogatory or false statements with respect to
Executive. 
 10. Confidentiality. By employment with Cytyc, Executive has had, or will have, contact with and gain knowledge of
certain confidential and proprietary information and trade secrets, including without limitation, analyses of Cytyc’s prospects and opportunities; programs (including advertising); direct mail and telephone lists, customer lists and potential
customer lists; Cytyc’s plans for present and future developments; marketing information including strategies, tactics, methods, customer’s market research data; financial information, including reports, records, costs, and performance
data, debt arrangements, holdings, income statements, annual and/or quarterly statements and accounting records and/or tax returns; operational information, including operating procedures, products, methods, service techniques, “know-how”,
tooling, plans, concepts, designs, specifications, trade secrets, processes, methods and suppliers; technical information, including computer software programs; research and development projects; product formulae, processes, inventions, designs, or
discoveries, which information Cytyc treats as confidential. Executive agrees that Executive will not communicate or disclose to any third party or use for Executive’s own account, without the written consent of Cytyc, any of the aforementioned
information or material, except as required by law, unless and until such information or material becomes generally available to the public through sources other than Executive. 
  

 -4- 

 Executive will deliver to Cytyc all property, documents, or materials in his possession or custody, of
any nature belonging to Cytyc whether in original form or copies of any kind, including any trade secrets and proprietary information upon the Separation Date. 
 11. Assignment. Executive hereby represents and warrants to Cytyc that Executive has not assigned any claim that Executive may or might have against Cytyc, from which Cytyc would otherwise be released pursuant
to this Release Agreement, to any third party. 
 12. Governing Law. This Release Agreement shall be governed by and construed in
accordance with the laws of the Commonwealth of Massachusetts, without giving effect to conflict of laws principles. 
 13. Voluntary
Assent. The Executive confirms that no other promises or agreements of any kind have been made by any person to cause him to sign this Release Agreement except as otherwise as noted herein, and that he fully understands the meaning and intent of
this Release Agreement. Executive agrees that this is the entire agreement and understanding between Cytyc and him or herself. 
 14.
Severability. The provisions of this Release Agreement are severable. If any provision of this Release Agreement is declared invalid or unenforceable, any court of competent jurisdiction reviewing such provision shall enforce the provision to
the maximum extent permissible under applicable law. Any ruling will not affect the validity and enforceability of any other provision of the Release Agreement. 
 15. Notices. Any and all notices or other communications required or permitted to be given in connection with this Agreement shall be in writing (or in the form of a facsimile or electronic transmission)
addressed as provided below and shall be (i) delivered by hand, (ii) transmitted by facsimile or electronic mail with receipt confirmed, (iii) delivered by overnight courier service with confirmed receipt or (iv) mailed by first
class U.S. mail, postage prepaid and registered or certified, return receipt requested: 
 If to Cytyc send c/o Hologic, Inc. at: 

Hologic, Inc. 
 35 Crosby Drive 

Bedford, Massachusetts 07130 
 Attention:
David Brady, Senior Vice President 
 Facsimile No: (781) 280-0674 
 Email Address: dbrady@hologic.com 
 with a copy to: 
 James L. Hauser, Esq. 
 Brown Rudnick Berlack Israels LLP 
 One Financial Center 
 Boston, MA 02111 
 E-Mail Address:
jhauser@brownrudnick.com 
  

 -5- 

 If to the Executive, to: 
 Daniel J. Levangie 
 120 Commonwealth Avenue, Apt. 4 
 Boston, Massachusetts 02116 
 E-Mail Address:

 with a copy to: 
 Steven D.
Weatherhead 
 Bello Black & Welsh LLP 
 One Exeter Place 
 699 Boylston Street, 10th Floor 
 Boston, MA 02116 
 and in any case at such other address as the addressee shall have specified by written notice. Any notice or other communication given in accordance with this
Section 15 shall be deemed delivered and effective upon receipt, except those notices and other communications sent by mail, which shall be deemed delivered and effective three (3) business days following deposit with the United States
Postal Service. All periods of notice shall be measured from the date of delivery thereof. 
 16. Entire Agreement. This Release
Agreement constitutes the entire agreement between the parties hereto with regard to the subject matter hereof, superseding all prior understandings and agreements, whether written or oral, including without limitation, the Hologic Change in Control
Agreement, Cytyc Change in Control Agreement and Retention Agreement, provided, however, that the Noncompetition Agreement; Section 3 of the Cytyc Change of Control Agreement; and Section 8 of the Retention Agreement shall
remain in full force and effect. 
 17. Remedies. Any breach or threatened breach by the Executive of the provisions of this Release
Agreement could result in irreparable and continuing damage to Cytyc for which there is no adequate remedy at law. In such event, Cytyc shall be entitled to seek injunctive relief and/or specific performance, and such other relief that may be proper
(including monetary damages, if proper). Any breach or threatened breach by Cytyc of the provisions of this Release Agreement could result in irreparable and continuing damage to the Executive for which there is no adequate remedy at law. In such
event, the Executive shall be entitled to seek injunctive relief and/or specific performance, and such other relief that may be proper (including monetary damages, if proper). 
  

 -6- 

 IN WITNESS WHEREOF, Cytyc and Executive have executed and delivered this Release Agreement as of the date
first written above. 
  

			
	 /s/ Daniel J. Levangie

	Daniel J. Levangie
	
	CYTYC CORPORATION
		
	By:	 	 /s/ Glenn P. Muir
 Glenn P.
Muir

  

 -7- 

 Exhibit A 
 Letter of Resignation 
 [DATE] 
 [ADDRESS] 
 Re: Cytyc Corporation and all direct and indirect subsidiaries 
 Dear [DISCUSS]: 
 In connection with the execution and
delivery of the Agreement and Plan of Merger by and among Hologic, Inc., Nor’easter Corp., and Cytyc Corporation, dated as of May 20, 2007 (the “Merger Agreement”), I hereby resign as an employee and from all officer positions
that I hold, if any, in Cytyc Corporation and all of its direct and indirect subsidiaries, effective immediately prior to the Effective Time (as defined in the Merger Agreement). I hereby acknowledge that I have never been employed by Hologic, Inc.

  

	
	Sincerely,
	
	  

	Daniel J. Levangie

  

 -8-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00131-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00131-of-00352.parquet"}]]